Previous 10 | Next 10 |
Stephen Mandel’s 13F portfolio value increased ~19% from $23.20B to $27.51B. The number of positions increased from 32 to 41. Lone Pine Capital increased MercadoLibre and DexCom while dropping PayPal and Capital One Financial. The top three positions are Shopify, Coupa Soft...
PHILADELPHIA, March 15, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced one oral presentation and two posters highlighting its development program for Pompe disease will be included at the 2021 MDA Virtual Clinical & Scientific Conference to be held ...
Image source: The Motley Fool. Amicus Therapeutics Inc (NASDAQ: FOLD) Q4 2020 Earnings Call Mar 1, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript
Amicus Therapeutics, Inc. (FOLD) Q4 2020 Earnings Conference Call March 1, 2021, 8:30 am ET Company Participants Andrew Faughnan - Head, IR John Crowley - Chairman & CEO Bradley Campbell - President & COO Jeff Castelli - CDO Daphne Quimi - CFO Hung Do - Chief Science Officer Mitchell ...
The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Amicus Therapeutics, Inc. 2020 Q4 - Results - Earnings Call Presentation
Amicus Therapeutics ([[FOLD]] -3.7%) FY results:Revenues: $260.88M (+43.2%).Net loss: ($276.9M) (+22.3%); loss/share: ($1.07) (+27.7%); Quick Assets: $483.3M (+6.8%).2021 guidance: Galafold revenue: $300M - 315M, to be driven by continued operational growth and commercial execution ...
Amicus Therapeutics (FOLD): FY GAAP EPS of -$1.07 misses by $0.08.Revenue of $260.88M (+43.2% Y/Y) beats by $1.35M.Shares +0.16% PM.Press Release For further details see: Amicus Therapeutics EPS misses by $0.08, beats on revenue
2020 Total Galafold Revenue of $260.9M; Increased 43 Percent Year-on-Year Continued Strong Global Growth of Galafold Expected in 2021 with Revenue of $300M-$315M AT-GAA Rolling BLA Submission in Pompe Disease Planned for Completion in 2Q21 and O...
This investment strategy holds a maximum of 50 consensus stock picks from 40 hedge funds with more than $3,500 million Assets Under Management. Changes in the holdings occur only every three months when the end of the quarter 13F filings become public information; the latest date was ...
PHILADELPHIA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences: SVB Leerink 10 th Annual Global Healthca...
News, Short Squeeze, Breakout and More Instantly...
Amicus Therapeutics Inc. Company Name:
FOLD Stock Symbol:
NASDAQ Market:
Amicus Therapeutics Inc. Website:
2024-07-01 16:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 11, 2024, at 4:00 p.m. E.T. A live audio...
PRINCETON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the Galien Foundation has awarded the 2024 Prix Galien U.K....